Over the last 10 years, West Pharmaceutical Services stock has attracted buying interest at this level 7 times and has ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Alnylam could have a catalyst on the way.

Novartis (NVS) is trading at new all-time highs on Monday. ・Shares are up nearly 50% over the past 52 weeks. ・NVS maintains a ...

Both could reward patient investors down the line.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the ridiculously cheap stocks to buy now. As of December 26, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has a ‘Buy’ rating from 74% of the analysts ...

This biotech has candidates in late-stage clinical development.

Amid the expected positive clinical trial results, Legend Biotech has also reiterated plans to achieve profitability in 2026.

Citi launched broad coverage of major European pharmaceutical companies with a mixed outlook, issuing Buy ratings on AstraZeneca and Novartis while taking a more cautious stance on GSK, Novo Nordisk ...

Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check out why INO stock is a buy.